title: Prospective study of Helicobacter pylori antigens and gastric noncardia cancer risk in the nutrition intervention trial cohort.
abstract: Helicobacter pylori (H. pylori) infection is the strongest known risk factor for gastric noncardia adenocarcinoma (GNCA). We used multiplex serology to determine whether seropositivity to 15 H. pylori proteins is associated with the subsequent development of noncardia gastric cancer in Linxian, China. We included 448 GNCA cases and 1242 controls from two time points within the Linxian General Population Nutrition Intervention Trial, Linxian. H. pylori multiplex seropositivity was defined as positivity to ≥4 of the 15 included antigens. Odds ratios (ORs) and 95% confidence intervals (CIs) were adjusted for major GNCA risk factors. In addition, we undertook a meta-analysis combining H. pylori multiplex serology data from both time points. H. pylori multiplex seropositivity was associated with a significant increase in risk of GNCA at one time point (1985; OR: 3.44, 95% CI: 1.91, 6.19) and this association remained significant following adjustment for H. pylori or CagA ELISA seropositivity (OR: 2.92, 95% CI: 1.56, 5.47). Combining data from both time points in a meta-analysis H. pylori multiplex seropositivity was associated with an increased risk of GNCA, as were six individual antigens: GroEL, HP0305, CagA, VacA, HcpC and Omp. CagM was inversely associated with risk of GNCA. We identified six individual antigens that confer an increase in risk of GNCA within this population of high H. pylori seroprevalence, as well as a single antigen that may be inversely associated with GNCA risk. We further determined that the H. pylori multiplex assay provides additional information to the conventional ELISA methods on risk of GNCA.
authors.affiliation: Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD.
authors.forename: Gwen
authors.initials: G
authors.lastname: Murphy
authors.affiliation: Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD.
authors.forename: Neal D
authors.initials: ND
authors.lastname: Freedman
authors.affiliation: Division of Genome Modifications and Carcinogenesis, Infection and Cancer Program, German Cancer Research Center (DKFZ), Heidelberg, Germany.
authors.forename: Angelika
authors.initials: A
authors.lastname: Michel
authors.affiliation: Department of Epidemiology, Cancer Institute, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
authors.forename: Jin-Hu
authors.initials: JH
authors.lastname: Fan
authors.affiliation: Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD.
authors.forename: Philip R
authors.initials: PR
authors.lastname: Taylor
authors.affiliation: Division of Genome Modifications and Carcinogenesis, Infection and Cancer Program, German Cancer Research Center (DKFZ), Heidelberg, Germany.
authors.forename: Michael
authors.initials: M
authors.lastname: Pawlita
authors.affiliation: Department of Epidemiology, Cancer Institute, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
authors.forename: You-Lin
authors.initials: YL
authors.lastname: Qiao
authors.affiliation: Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD.
authors.forename: Han
authors.initials: H
authors.lastname: Zhang
authors.affiliation: Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD.
authors.forename: Kai
authors.initials: K
authors.lastname: Yu
authors.affiliation: Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD.
authors.forename: Christian C
authors.initials: CC
authors.lastname: Abnet
authors.affiliation: Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD.
authors.forename: Sanford M
authors.initials: SM
authors.lastname: Dawsey
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000453:epidemiology* / Q000382:microbiology; D000368:Aged; D000942:Antigens, Bacterial / Q000276:immunology*; D005260:Female; D016481:Helicobacter Infections / Q000097:blood / Q000453:epidemiology / Q000276:immunology*; D016480:Helicobacter pylori / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012307:Risk Factors; D016036:Seroepidemiologic Studies; D013274:Stomach Neoplasms / Q000097:blood / Q000453:epidemiology* / Q000382:microbiology
chemical_list: D000942:Antigens, Bacterial
keywords: Helicobacter pylori; esophageal cancer; gastric cancer; multiplex serology
references.citation: Proc Natl Acad Sci U S A. 2000 Feb 1;97(3):1263-8
references.pmid: 10655519
references.citation: Am J Pathol. 2001 Feb;158(2):647-54
references.pmid: 11159201
references.citation: J Natl Cancer Inst. 2001 Feb 7;93(3):226-33
references.pmid: 11158192
references.citation: N Engl J Med. 2001 Sep 13;345(11):784-9
references.pmid: 11556297
references.citation: Mol Microbiol. 2001 Dec;42(5):1337-48
references.pmid: 11886563
references.citation: Proteomics. 2002 Mar;2(3):313-24
references.pmid: 11921447
references.citation: Int J Cancer. 2004 Jan 20;108(3):456-63
references.pmid: 14648714
references.citation: Nat Rev Cancer. 2004 Sep;4(9):688-94
references.pmid: 15343275
references.citation: J Natl Cancer Inst. 1993 Sep 15;85(18):1483-92
references.pmid: 8360931
references.citation: Ann Epidemiol. 1993 Nov;3(6):577-85
references.pmid: 7921303
references.citation: J Biol Chem. 1995 Jul 28;270(30):17771-7
references.pmid: 7629077
references.citation: J Natl Cancer Inst. 1995 Dec 6;87(23):1777-80
references.pmid: 7473834
references.citation: Infect Immun. 1998 Mar;66(3):1023-7
references.pmid: 9488391
references.citation: Int J Cancer. 2005 Jan 20;113(3):456-63
references.pmid: 15455378
references.citation: Infect Immun. 2005 Aug;73(8):4732-42
references.pmid: 16040986
references.citation: Clin Chem. 2005 Oct;51(10):1845-53
references.pmid: 16099939
references.citation: Infect Immun. 2006 Jan;74(1):425-34
references.pmid: 16368998
references.citation: J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Mar 20;833(1):63-79
references.pmid: 16483854
references.citation: J Natl Cancer Inst. 2006 Oct 18;98(20):1445-52
references.pmid: 17047193
references.citation: Br J Cancer. 2007 Jan 15;96(1):172-6
references.pmid: 17179990
references.citation: J Natl Cancer Inst. 2009 Apr 1;101(7):507-18
references.pmid: 19318634
references.citation: Cancer Res. 2009 Apr 1;69(7):2973-80
references.pmid: 19318564
references.citation: Cancer Res. 2009 Aug 1;69(15):6164-70
references.pmid: 19602590
references.citation: Helicobacter. 2009 Dec;14(6):525-35
references.pmid: 19889070
references.citation: Nat Rev Microbiol. 2009 Dec;7(12):887-94
references.pmid: 19898491
references.citation: Cancer Epidemiol Biomarkers Prev. 2012 Dec;21(12):2185-92
references.pmid: 23035179
references.citation: Am J Clin Nutr. 2013 Nov;98(5):1289-97
references.pmid: 24025629
references.citation: Hepatology. 2014 Dec;60(6):1963-71
references.pmid: 24797247